Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy
Recruiting now Phase 4 NCT06908694
Run by Hamilton Health Sciences Corporation · for 18 and older · Men
What this study is about
GAIN PC CONTROL is a study investigating Glucagon-Like Peptide-1 Receptor Agonists in men with prostate cancer who are being treated with androgen deprivation therapy.
Who can join (things the study team will check)
✅ You may be able to join if…
- Have a physician diagnosis of PC
- Must be receiving or planned to receive ADT (gonadotropin releasing hormone agonist or antagonist ± androgen receptor pathway inhibitor)
- Elevated BMI
- ≥30kg/m2 or
- ≥27kg/m2 in the presence of at least one of hypertension, type 2 diabetes, obstructive sleep apnea or dyslipidemia
🚫 You may not be able to join if…
- Type 1 diabetes
- Taking a GLP-1 RA
- <18 years of age
- History of pancreatitis
- Personal or family history of medullary cancer of the thyroid
- Multiple endocrine neoplasia type 2
Where this trial is running
- Juravinski Cancer Centre, Hamilton, Ontario, Canada
Who to contact
Sarah Karampatos, BASc, MSc · 905-296-5795 · sarah.karampatos@phri.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT06908694.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.
Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.